A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression

Charlotte De Bondt; Annemiek Snoeckx; Jo Raskin

doi:10.5334/jbsr.1907

Abstract

We report the case of a 72-year-old female never-smoker with stage IV endothelial growth factor receptor (EGFR) mutated lung adenocarcinoma. This patient was started on first line tyrosine kinase inhibitor (TKI) and seemingly developed new bone metastases under this treatment. As there was a remarkable discrepancy between the partial response seen in the primary tumor and non-osseous metastatic locations, the possibility of a bone flare phenomenon was considered. In this case report, we demonstrate that new bony lesions are not always synonymous with disease progression.

Publisher's Note: A corrigendum relating to this article has been published at http://doi.org/10.5334/jbsr.2163.

References

1 Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol. 2013; 2(1): 22–9. DOI: 10.1016/j.jbo.2012.12.004
Back to article
2 Reddington JA, Mendez GA, Ching A, Kubicky CD, Klimo P, Jr, Ragel BT. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic. Surg Neurol Int. 2016; 7(Suppl 13): S361–S365. DOI: 10.4103/2152-7806.182549
Back to article
3 Al-Nabhani K, Syed R, Haroon A, Almukhailed O, Bomanji J. Flare response versus disease progression in patients with non-small cell lung cancer. J Radiol Case Rep. 2012; 6(11): 34–42. DOI: 10.3941/jrcr.v6i11.1109
Back to article
4 Bersanelli M, Bini P, Rabaiotti E, et al. Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: A potential blunder. Tumori Journal. 2017; 103(1): 66–71. DOI: 10.5301/tj.5000423
Back to article
5 Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995; 13(5): 1123–8. DOI: 10.1200/JCO.1995.13.5.1123
Back to article
6 Yu YS, Li WH, Li MH, Meng X, Kong LI, Yu JM. False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature. Oncol Lett. 2015; 10(6): 3585–90. DOI: 10.3892/ol.2015.3753
Back to article
7 Pluquet E, Cadranel J, Legendre A, et al. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. J Thorac Oncol. 2010; 5(4): 491–6. DOI: 10.1097/JTO.0b013e3181cf0440
Back to article
8 Lind JS, Postmus PE, Smit EF. Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: A brief report. J Thorac Oncol. 2010; 5(4): 554–7. DOI: 10.1097/JTO.0b013e3181d3e47e
Back to article
9 Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009; 34(6): 346–9. DOI: 10.1097/RLU.0b013e3181a344df
Back to article
10 Gelsomino F, Ambrosini V, Melotti B, Sperandi F, Ardizzoni A. Pitfalls in oncology: Osteoblastic response mimicking bone progression during ceritinib treatment in ALK-rearranged NSCLC. J Thorac Oncol. 2016; 11(8): e99–e101. DOI: 10.1016/j.jtho.2016.04.002
Back to article
11 Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005; 12(2): 471–82. DOI: 10.1677/erc.1.00956
Back to article
12 Zhang X, Tamasi J, Lu X, et al. Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo. J Bone Miner Res. 2011; 26(5): 1022–34. DOI: 10.1002/jbmr.295
Back to article
13 Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007; 13(20): 6087–92. DOI: 10.1158/1078-0432.CCR-07-0591
Back to article
14 Emami KH, Corey E. When prostate cancer meets bone: Control by wnts. Cancer Lett. 2007; 253(2): 170–9. DOI: 10.1016/j.canlet.2006.12.040
Back to article
15 Devarakonda S, Masood A, Govindan R. Next-generation sequencing of lung cancers: Lessons learned and future directions. Hematol Oncol Clin North Am. 2017; 31(1): 1–12. DOI: 10.1016/j.hoc.2016.08.008
Back to article
16 Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1): 8. DOI: 10.1186/s13073-019-0703-1
Back to article

A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression

Abstract

Paradigm

My account